Head to Head Comparison: Harvard Bioscience (HBIO) and Horiba (HRIBF)

Harvard Bioscience (NASDAQ: HBIO) and Horiba (OTCMKTS:HRIBF) are both computer and technology companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, earnings, risk and profitability.

Earnings & Valuation

How to Become a New Pot Stock Millionaire

This table compares Harvard Bioscience and Horiba’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Harvard Bioscience $101.88 million 2.04 -$860,000.00 $0.05 117.00
Horiba $1.57 billion 1.66 $130.57 million $3.07 19.88

Horiba has higher revenue and earnings than Harvard Bioscience. Horiba is trading at a lower price-to-earnings ratio than Harvard Bioscience, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Harvard Bioscience and Horiba, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Harvard Bioscience 0 0 2 0 3.00
Horiba 0 0 0 0 N/A

Harvard Bioscience presently has a consensus price target of $9.00, suggesting a potential upside of 53.85%. Given Harvard Bioscience’s higher possible upside, analysts clearly believe Harvard Bioscience is more favorable than Horiba.

Volatility & Risk

Harvard Bioscience has a beta of 1.27, suggesting that its stock price is 27% more volatile than the S&P 500. Comparatively, Horiba has a beta of 2.09, suggesting that its stock price is 109% more volatile than the S&P 500.


This table compares Harvard Bioscience and Horiba’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Harvard Bioscience -0.85% 2.34% 1.64%
Horiba N/A N/A N/A

Insider & Institutional Ownership

62.3% of Harvard Bioscience shares are held by institutional investors. 7.6% of Harvard Bioscience shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.


Harvard Bioscience beats Horiba on 8 of the 13 factors compared between the two stocks.

About Harvard Bioscience

Harvard Bioscience, Inc. is a developer, manufacturer and marketer of a range of scientific instruments, systems and lab consumables used for basic research, drug discovery, clinical and environmental testing. The Company’s products are sold to thousands of researchers in over 100 countries through its global sales organization, Websites, catalogs and through distributors. The Company’s product range is organized into three commercial product families: Cell and Animal Physiology (CAP), Lab Products and Services (LPS), and Molecular Separation and Analysis (MSA). The Company sells these products under brand names, including Harvard Apparatus, KD Scientific, Denville Scientific, AHN, Hoefer, Biochrom, BTX, Warner Instruments, MCS, HEKA, Hugo Sachs Elektronik, Panlab, Coulbourn Instruments, TBSI and CMA Microdialysis. The Company’s products consist of instruments, consumables and systems that are made up of various individual products.

Receive News & Ratings for Harvard Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply